Ultragenyx Pharmaceutical Inc.
NEWS
Ultragenyx Pharmaceutical Inc. today announced that it will present at the following upcoming investor conferences
Ultragenyx Pharmaceutical Inc. today reported its financial results and corporate update for the quarter ended September 30, 2018.
Ultragenyx Pharmaceutical Inc. today announced that it will host a conference call on Monday, November 5, 2018 at 5pm ET to discuss third quarter 2018 financial results and provide a corporate update.
Biopharma companies name new members of their leadership teams. Who made big moves this week?
Ultragenyx CEO to present Keynote Address at the 2018 CDKL5 Forum hosted by the Loulou Foundation
Shares of Ultragenyx are down more than 15 percent this morning after the company announced its Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome.
CODA Biotherapeutics launched in South San Francisco with a $19 million Series A financing.
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureTech Ventures, responded to the editorial in Forbes. Let’s take a look.
JOBS
IN THE PRESS